A phase II trial of pembrolizumab plus olaparib for the treatment of patients with persistent/recurrent endometrial cancers. E7386 study 102: Global dose-expansion cohort of E7386 + lenvatinib (LEN) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results